Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional factor that stimulates epithelial cell mitogenesis, motility, invasion, and morphogenesis. Its receptor is encoded by the MET proto-oncogene, a transmembrane receptor tyrosine kinase. Several studies have suggested a role for MET as a dominant oncogene in tumor development and progression. Conversely, MET is located at a region on chromosome 7q31 frequently deleted in carcinomas, suggesting that recessive mutations in MET may exist in certain cancers. To facilitate a search for mutations in MET, we have obtained the intron-exon structure of the human MET gene. We present the genomic structure of the ®rst member of the Met receptor family to be characterized. Interestingly, MET contains a large second exon of 1214 nucleotides. We show that this exon, containing the AUG for the Met receptor, is frequently skipped in normal human tissues and cell lines, and corresponds to a ubiquitously expressed 7 kb Met transcript. This transcript yields no detectable protein product in vivo. Thus, unlike other genes, in which alternative splicing often gives rise to proteins with distinct activities, exon-skipping of MET exon 2 is predicted to decrease the abundance of a Met mRNA encoding a functional Met receptor.
Introduction
The MET gene encodes a transmembrane protein receptor tyrosine kinase (Park et al., 1987) whose ligand, Hepatocyte Growth Factor/Scatter Factor (HGF/SF) (Bottaro et al., 1991; Naldini et al., 1991) , is a mesenchymally-derived growth factor. Addition of HGF/SF to epithelial cells produces pleiotropic biological eects, including mitogenesis of primary hepatocytes and renal tubule cells, and scatter, invasion and branching tubulogenesis of epithelial cells (reviewed in Rosen et al., 1994) . During development, HGF/SF is expressed in mesenchymal tissue in close proximity to Met-expressing epithelium (Sonnenberg et al., 1993) , supporting a role for Met-HGF/SF signaling pathways in epithelial-mesenchymal interactions in vivo. Genetic studies show a critical role for Met and HGF/SF in normal embryonic development, and have demonstrated a role for Met and HGF/SF in the development of liver and placenta, the development and innervation of skeletal muscle, the ductal growth of mouse mammary explants, and directing the growth of axonal growth cones (Schmidt et al., 1995; Uehara et al., 1995; Yang et al., 1995; Ebens et al., 1996; Maina et al., 1996; Takayama et al., 1996; Yang et al., 1996) .
The Met receptor and HGF/SF are also implicated in oncogenesis. Met was ®rst isolated as an oncogenic variant, generated following a genomic rearrangement (Park et al., 1986) . Deregulation of the Met receptor via an autocrine loop transforms ®broblasts in culture (Rong et al., 1994) , and transgenic mice overexpressing HGF/SF exhibit tumorigenesis of various organs (Takayama et al., 1997) . Met is overexpressed and/or deregulated in diverse human tumors including gastric, colorectal, thyroid and ovarian carcinomas, leukemia and sarcomas (Di Renzo et al., 1992 Liu et al., 1992; Rong et al., 1993 Rong et al., , 1995 Jucker et al., 1994; Scotlandi et al., 1996; Yonemura et al., 1996) . Although in some cases, constitutive activation of Met in the absence of ligand has been correlated with ampli®cation and overexpression of a wild-type Met protein (Giordano et al., 1989b) , it is possible that activating mutations in MET may exist in human cancers. In addition, MET is located on a 1000 kilobase (kb) region of chromosome 7q31 that is deleted in breast cancer (Lin et al., 1996) . Deletions in this region of 7q31 have also been described for prostate and ovarian carcinomas (Zenklusen et al., 1994 (Zenklusen et al., , 1995 Takahashi et al., 1995) . Since loss of chromosomal regions are generally thought to correlate with the presence of recessive mutations, this would suggest that recessive mutations may be found in MET in these cancer types. Thus, in a situation analogous to the Ret receptor tyrosine kinase, where both activating and inactivating mutations have been described in human disease (reviewed in Pasini et al., 1996) , dierent mutations aecting the activity of Met may be found in various cancers.
MET is the prototype for a family of receptor tyrosine kinases, including RON and the chicken c-sea gene (Hu et al., 1993; Ronsin et al., 1993) , that have overall sequence and protein structural similarity. The major MET product is synthesized as a single chain precursor of 170 kDa that is cleaved post-translationally to yield a transmembrane b-subunit of 145 kDa containing the intracellular tyrosine kinase domain and an a-subunit of 45 kDa that remains extracellular (Giordano et al., 1989a; Rodrigues et al., 1991) . The a-and b-subunits are linked together through disul®de bonds to form a mature heterodimeric Met receptor of 190 kDa (p190Met) which, upon binding HGF/SF, becomes phosphorylated on tyrosine residues in the bsubunit (Bottaro et al., 1991; Naldini et al., 1991) . The p190Met high-anity HGF/SF receptor is encoded by the most abundant Met mRNA, which is 8 kb in size (Rodrigues et al., 1991) . However, another Met transcript of 7 kb is observed by Northern hybridization analysis of RNA from cell lines and tissues (Park et al., 1986; Giordano et al., 1989b) . The functional signi®cance of this transcript and its protein product is unknown.
To understand the biochemical signi®cance of alternative splicing in the Met receptor and to facilitate a search for mutations within MET in human cancer, we have obtained the intron-exon structure of the human MET gene. We have cloned and elucidated the structure of an alternatively spliced Met cDNA that corresponds to the ubiquitously expressed Met mRNA of 7 kb. We show that the 7 kb Met mRNA lacks exon 2 of MET, which contains the AUG for the p190Met receptor product. Interestingly, exon 2 is skipped in normal human tissues and cell lines. However, this transcript yields no detectable protein product in vivo and only low levels (55% of wild type receptor) of multiple truncated proteins in transient assays. Thus, the 7 kb Met transcript is unlikely to give rise to a protein product in vivo and we suggest that exon-skipping may represent a mechanism that regulates the abundance of the 8 kb Met mRNA encoding a functional Met receptor.
Results

Intron ± exon organization of the human MET gene
To isolate the MET genomic locus, cDNA corresponding to the 8 kb Met transcript, which encodes the p190Met receptor, was used as a probe to screen two libraries prepared from human genomic DNA. The entire MET locus was isolated in nine overlapping l phage clones from a human placental genomic library (Rodrigues et al., 1991) and two cosmid clones from the Lawrence Livermore National Laboratory chromosome 7-speci®c cosmid library (obtained from Dr SW Scherer). DNA prepared from the l phage and cosmid genomic clones was used to analyse MET genomic structure. Oligonucleotide primers derived from the Met cDNA sequence (Park et al., 1987) were used to obtain sequence information from each clone. The intron ± exon boundaries were mapped by sequencing each exon in its entirety, along with portions of the adjacent introns (Table 1) . The approximate size of each intron was estimated by PCR ampli®cation of human genomic DNA using oligonucleotide primers anking each intron (Table 1 and data not shown). Introns 1 and 2 gave variable-sized ampli®cation products. Therefore, the exact sizes of these introns were obtained from sequence information recently deposited at the Human Genome Sequencing Project's World Wide Web site (http://genome.wustl.edu/gsc/ gschmpg.html).
A graphical representation of the MET gene is shown in Figure 1a . All MET exons were found to be¯a nked by the canonical consensus splice sites; AG at the 3' splice site, and GT at the 5' splice site (Table 1) (Breathnach and Chambon, 1981) . The exons range in size, from 81 nucleotides (nt) (exon 16) to 2.5 kb for the last exon (exon 21), which encodes the carboxyterminus of the Met protein and a long 3'UTR (untranslated region) ( Figure 1b and Table 1 ). The sizes of the introns range between 100 nt and 31 kb. Exon 1 of MET is non-coding, and contains most of the 5'UTR. Exon 2 is the largest internal coding exon of MET (1214 nt), and contains 14 nt of 5' untranslated sequence followed by the initiating methionine codon. Thus, the 4170 nt open reading frame coding for the p190Met receptor protein is distributed over 20 exons. The correlation of the exon structure of MET with the functional domains of the Met protein is shown in Figure 1b . Exon 2 contains the entire coding sequence for the 45 kDa a-chain of the p190Met receptor, whereas the transmembrane 145 kDa b-chain is encoded by exons 2 ± 21.
Cloning and characterization of an alternatively spliced Met mRNA isoform
Northern hybridization analysis of RNA derived from various cell lines reveals that multiple transcripts are expressed from the MET locus, the most abundant being estimated to be 8 kb and 7 kb in size (Park et al., 1986; Giordano et al., 1989b) . Using a probe derived from the cDNA corresponding to the major 8 kb Met mRNA (probe A; nt +641 to +2055; see Figure 2c ), Met transcripts corresponding to the 8 kb and 7 kb Met mRNAs are detected in various human cell lines (Figure 2a) . We have previously isolated cDNA, pOK1 (6.8 kb) , that corresponds to the most abundant 8 kb Met transcript, and shown that it encodes the p190Met receptor heterodimer (Rodrigues et al., 1991) . A second cDNA, pHOS (6.7 kb), corresponds to an 8 kb Met transcript, present at low levels, and results from the use of an alternate splice acceptor for exon 10, located 54 nt upstream of the p190Met splice acceptor site (Park et al., 1987; Rodrigues et al., 1991) . The 7 kb Met transcript has not been characterized. We show that a probe derived from the 5' portion of the Met cDNA (probe B; nt7194 to +641; Figure 2c ), which contains sequences derived mainly from exon 2, hybridizes to the 8 kb Met transcript, but only weakly to the 7 kb Met isoform (Figure 2b ), suggesting that the 7 kb transcript is lacking these sequences.
To preferentially isolate cDNA clones that correspond to the 7 kb Met transcript, we screened a cDNA library prepared from a human cell line that expresses the 7 kb Met mRNA at high levels (Okajima, Figure  2a ) with probes A and B (Figure 2c) , and chose clones which hybridized strongly with probe A, but not with probe B. Two clones with this pro®le, pOK14 (3196 nt), and pOK8 (1650 nt), were characterized further and sequenced (Figure 2c ). The pOK14 cDNA extended from position 7145 to +4265 of MET, and contained a deletion of 1214 bp from 714 to 1200 (inclusive) (Figure 2c ), whereas the pOK8 cDNA extended from 7382 to +2482, and contained the same deletion as pOK14 (Figure 2c) . Neither of the pOK14 nor pOK8 cDNA clones contains a poly(A) + tail, and appear to have been reverse-transcribed following hybridization of the oligo-dT primer to internal A-rich regions. However, the longer clone, pOK14, contains part of the 5'UTR as well as the stop codon at base number +4170 used for the p190Met protein, and lacks only part of the long 3'UTR last exon of MET (from +4265 to the poly(A) + addition site; Figure 2c ). Thus, the size of the pOK14 cDNA (3.19 kb) plus the additional 3'UTR (2.2 kb, Figure 2c ) and 5'UTR (267 bp, Figure 2c ), generates a transcript of 5.66 kb, which is consistent with the size of pOK1 cDNA (6.8 kb) minus exon 2 (1214 nt). Moreover, the structure of the pOK14 and pOK8 clones are consistent with that expected for the 7 kb Met mRNA from Northern analysis, in that they would hybridize with probe A but fail to hybridize or hybridize poorly with probe B (7194 to +641).
The pOK14 and pOK8 cDNAs correspond to a ubiquitously expressed, alternatively spliced Met mRNA lacking exon 2
The pOK14 and pOK8 clones contain no new sequences when compared with the full length Met cDNA pOK1 (Rodrigues et al., 1991) (data not shown). To verify that pOK14 and pOK8 are authentic copies of a Met mRNA, we performed S1 nuclease protection analyses on RNA isolated from various human cell lines. A 2 kb fragment derived from the 5' end of the pOK8 clone and containing vector sequences (856 bp) was end-labeled (at position +1964 in Met; Figure 3a ) and hybridized with RNA derived from cell lines shown to express the 8 kb and 7 kb Met mRNAs by Northern analysis (Figure 2a and data not shown). Following S1 nuclease digestion, two fragments were protected (Figure 3b ), one of 1144 nt that corresponds to a Met transcript lacking exon 2 (see predicted fragments; Figure 3a ), and one of 764 nt corresponding to a Met transcript containing exon 2 (see Figure 3a) . Thus, the S1 nuclease protection assay demonstrated that an alternatively spliced Met transcript lacking exon 2 that corresponds to the cloned cDNAs pOK14 and pOK8 is detected in each cell line tested (764 nt protected fragment; Figure 3b ).
To determine if a Met transcript lacking exon 2 is normally expressed in human tissues, we used RT ± (Gambarotta et al., 1994). b Exon 10 is subject to alternative splicing, in which this alternate splice junction located 54 bp upstream of the normal 5' splice site is used (Rodrigues et al., 1991) . c Exon 14 is alternatively spliced in mouse (Lee & Yamada, 1995) . The TPR-MET breakpoint occurs at exon 15 (Park et al., 1986) . e Base number is indicated above the ®rst nucleotide of each exon. Bases are numbered from the translation start site (+1) as de®ned by (Park et al., 1987) PCR (reverse transcriptase-polymerase chain reaction) to identify Met transcripts that either contain or lack exon 2 in a variety of human tissues. Oligonucleotide primer A, located within exon 1 and primer C, located within exon 3, were chosen¯anking exon 2 (Figure 4a ). These would generate an RT ± PCR product of 197 bp if exon 2 is not incorporated, whereas primer B (located within exon 2; see Figure  4a ) and primer C generate an RT ± PCR product of 225 bp, diagnostic for Met transcripts containing exon 2. All tissues exhibited a 197 bp RT ± PCR product with primers A and C, indicating the existence of a Met transcript lacking exon 2 (Figure 4b) . Moreover, the same tissues also express Met transcripts containing exon 2, as indicated by the presence of a 225 bp RT ± PCR product with primers B and C (Figure 4c ) or a 1411 bp RT ± PCR product with primers A and C (data not shown). Thus, Met transcripts lacking exon 2 are expressed in all normal human tissues tested. The pOK14 and 8 cDNAs lack the AUG for the p190Met receptor product
The cDNA clones pOK14 and pOK8 lack exon 2, which contains the initiating methionine codon of p190Met. Therefore, although pOK14 cDNA contains the stop codon for the p190Met receptor product (Figure 2c) , it would not be predicted to encode a fulllength Met protein. To examine the ability of these cDNAs to encode a protein, the pOK8 clone, which contained an additional 237 nt at its 5' end, was fused to pOK14, and the entire cDNA (pOK8+14) was examined for potential open reading frames (ORFs) (data not shown). Only one ORF of any signi®cant length was identi®ed, and it is 2880 nt long (the second largest is 129 nt). This pOK8+14 ORF (2880 nt) is in frame with the ORF of the p190Met protein ( Figure  5a ). The ®rst methionine codon, which is downstream from an in-frame stop codon (see Figure 5a) , is located within exon 3 of MET, at position +1291, and would be predicted to encode a protein of 960 amino acids with a size of *110 kDa. This protein would be identical to the p190Met protein in the carboxyterminus, but would lack 430 amino acids at the amino-terminus. Such a protein should be recognized by an antibody raised to a peptide in the carboxyterminus of p190Met (Ab144) (Rodrigues et al., 1991) . To identify and characterize this putative product, we generated a construct containing pOK8+14 ( Figure   5a ) in the mammalian expression vector pXMT2. Expression plasmids containing the pOK1 Met cDNA, which encodes the p190Met receptor, or the pOK8+14 Met cDNA were transiently transfected into COS-1 monkey cells and proteins were immunoprecipitated with Ab144. Immunoprecipitated proteins were separated by SDS ± PAGE and immunoblotted with Ab144 (Figure 5b) . The full-length pOK1 Met cDNA encoded high levels of Met proteins of predicted sizes; the Met receptor precursor (170 kDa) and the cleaved Met b-chain (145 kDa) (Figure 5b,  lane 2) . However, the pOK8+14 construct expressed low levels (55% of wild type) of multiple truncated proteins of 100 ± 110 kDa (Figure 5b, lane 3) . These data suggest that this construct is either ineciently translated or that its protein product is highly unstable. In support of these observations, when Met proteins were immunoprecipitated from cell lines which express Met transcripts containing exon 2 (8 kb) and lacking exon 2 (7 kb) (see Figures 2a and 3b) and immunoblotted with Ab144, the 145 kDa Met b-chain and 170 kDa Met precursor proteins can be readily detected, whereas Met proteins of *110 kDa were not readily detected (Figure 5c ). These data suggest that the 7 kb exon 2-skipped Met mRNA, although ubiquitously expressed, fails to give rise to a detectable protein product in vivo.
Discussion
To facilitate a search for mutations or alterations that activate or inactivate MET, we have obtained the intron ± exon structure of the human MET gene. We present the genomic structure for the ®rst member of the Met receptor tyrosine kinase family to be characterized. Moreover, we report extensive exonskipping in human Met mRNA in normal tissue and tumor cell lines, generating a transcript that lacks the large internal coding exon 2.
The human MET gene consists of 21 exons distributed over *130 kb of genomic DNA ( Figure  1 ). The exon nucleotide sequence obtained by the sequencing of genomic DNA matched that of previously sequenced cDNAs corresponding to the 8 kb Met mRNA (Park et al., 1987; Rodrigues et al., 1991) . All MET exons were found to be¯anked by the canonical consensus splice donor and acceptor sites; AG at the 3' splice site, and GT at the 5' splice site (Table 1) (Breathnach and Chambon, 1981) . As a consequence of the intron ± exon distribution, the extracellular and transmembrane portion of the p190Met receptor is encoded by exons 2 ± 13 which span *100 kb of genomic DNA, whereas the cytoplasmic portion containing the catalytic kinase domain is encoded by exons 14 ± 21 that span *30 kb (Figure 1) .
Interestingly, missense mutations, predicted to cause constitutive activation of the Met kinase in the absence of ligand, have recently been identi®ed in MET in patients with hereditary and spontaneous papillary renal carcinoma, suggesting that constitutive activation of Met contributes to this disease (Schmidt et al., 1997) . The multiple independent mutations thought to activate Met in papillary renal carcinomas are localized to the cytoplasmic kinase domain in exons 17, 18 and 19, and include three which are similar to mutations P-labeled antisense probe was generated from the plasmid containing pOK8 cDNA lacking exon 2 as described in Materials and methods. Vector sequences are indicated by the dashed line. This probe was hybridized to 40 mg of total RNA prepared from A549, Okajima, SW620 and Colo6 cells. (b) Following hybridization, samples were treated with S1 nuclease and then analysed on a 4% denaturing gel. FX DNA digested with HaeIII and HincII serves as molecular weight markers. The sizes of these markers are indicated on the right. Protected fragments of 1144 nt, corresponding to the exon 2-lacking Met mRNA and 764 nt, corresponding to exon 2-containing mRNA are detected that activate the Ret and Kit receptor tyrosine kinases (Schmidt et al., 1997) . However, mutations that activate receptor tyrosine kinases generally fall into two classes; those localized to the extracellular or transmembrane domain that promote receptor dimerization/oligomerization, and those localized to the kinase domain that alter catalytic activity or substrate speci®city (Rodrigues and Park, 1994) . Thus, the intron ± exon structure of MET presented here will now allow a critical evaluation of mutations in the entire Met receptor in other human cancers.
MET is unique among the receptor tyrosine kinases whose genomic structure has been determined to date, due to the presence of a large internal coding exon, exon 2. Exon 2 is absent in Met cDNA clones pOK14 and pOK8 (Figure 2 and data not shown). The structure of these clones is consistent with that of a ubiquitously expressed 7 kb Met mRNA. By Northern hybridization analyses, the 7 kb Met mRNA fails to hybridize with a probe derived mainly from exon 2 (Figure 2b) . Moreover, S1 nuclease analyses demonstrate that Met cDNA clones pOK14 and pOK8 correspond to an authentic Met mRNA in human cell lines expressing the 7 kb Met transcript ( Figure  3b) . All of the Met cDNAs that have been characterized to date (Park et al., 1987; Rodrigues et al., 1991) , including pOK14 and pOK8, share 5'UTR sequences, suggesting that they are transcribed from the same promotor (Gambarotta et al., 1994) . Therefore, we conclude that the 7 kb and 8 kb Met mRNAs are derived from the same pre-mRNA by alternative splicing of exon 2.
The pOK8 and pOK14 Met cDNA clones lack the initiating methionine codon of p190Met which is present in exon 2. From sequence analysis, the pOK8+14 cDNA contains only one ORF, which would initiate at an AUG in exon 3 (position +1291 in Met), and would correspond to the ORF for the p190Met receptor (Figure 5a ). Although by Northern blot analysis the 7 kb Met isoform is expressed in relative abundance in many human cell lines ( Figure  2a) , and S1 nuclease protection assays demonstrate that a mRNA corresponding to pOK14 or pOK8 is expressed (Figure 3b ), a protein product predicted from this message was not readily detected in these cell lines (Figure 5c) . Similarly, the expression of pOK8+14 cDNA in COS-1 cells in transient transfection assays yielded extremely low levels of truncated Met proteins of *100 ± 110 kDa when compared with cDNA encoding the p190Met product (Figure 5b ). This suggests that either the pOK8+14 cDNA is ineciently translated, or alternatively, that a protein product translated from this mRNA is rapidly degraded. Consistent with the former, the ®rst AUG codon of the pOK8+14 transcript (TTATTCAUGG) is in a poor Kozak consensus for initiation of translation and most importantly, lacks an adenine at position 73 (Kozak, 1991) . This suggests that the multiple products observed are initiated from downstream in-frame AUGs.
Work from many laboratories has shown that alternative splicing is determined by a balance of several pre-mRNA features, including splice site strength, exon size, presence of splicing enhancers or Primer A, which hybridizes to MET 744 to 724 in exon 1, and primer C, which hybridizes to MET +1367 to +1345 in exon 3, were used to amplify a 197 bp fragment corresponding to exon 2-lacking Met transcripts. A 197 bp PCR product was detected in all tissues studied. (c) Primer B, which hybridizes to MET +1142 to +1162 in exon 2, and primer C were used to amplify a 225 bp fragment corresponding to exon 2-containing Met transcripts. A 225 bp PCR product was detected in all tissues studied repressors and secondary structure (reviewed in Chabot, 1996; Manley and Tacke, 1996) . Several receptor tyrosine kinases undergo alternative splicing which generates proteins with similar or distinct structures and activities (Clary and Reichardt, 1994; Piao et al., 1994) . For example, alternative splicing in mouse of the conserved met exon 14 generates a protein which shows altered substrate speci®city (Lee and Yamada, 1995) . However, the alternatively spliced 7 kb Met mRNA presented here is unique in that it fails to synthesize a detectable protein product in vivo. This was unexpected since the 7 kb Met mRNA is the second most abundant Met mRNA and is ubiquitously expressed. The inclusion of dierentially-spliced exons is a highly regulated event, thought to be dependent on both enhancer sequences localized within either the exon or intron sequences, and the proteins that recognize them (reviewed in Chabot, 1996; Manley and Tacke, 1996) . However, since large internal exons are uncommon in vertebrate genes, with less than 1% of all primate internal exons studied being larger than 400 nt (Berget, 1995) , the mechanisms that regulate their splicing are poorly understood. In experimental systems, the arti®cial expansion of internal exons to more than 500 nt results in constitutive exon-skipping when¯anked by large introns (41500 nt) (Sterner et al., 1996) . Thus, this would predict that exon 2 of MET (1214 nt), which is signi®cantly larger than the average vertebrate exon (134 nt long) and is¯anked by two large introns (26 kb and 31 kb; see Table 1 ), may be ineciently included in mature Met mRNA. However, although the sequences or factors responsible for the observed alternative splicing of MET exon 2 are not understood, the inclusion of this exon in the 8 kb Met mRNA demonstrates that its presence is selected for in vivo. Moreover, the abundance of the 7 kb Met mRNA varies in tumor cell lines in culture (Figure 2a and data not shown) . Since exon-skipping of MET exon 2 is predicted to decrease the amount of mature mRNA encoding a functional Met receptor, in some circumstances, Met pre-mRNA splicing may represent a mechanism of regulating the amount of a functional Met product. Therefore, a further study of the prevalence of exon 2-skipping of MET during development and in human tumors is important, and will increase our understanding of the mechanisms of Met regulation in vivo.
Materials and methods
Isolation of genomic clones
A human genomic placental DNA library cloned in the bacteriophage vector lDASH 1 (Stratagene) (Rodrigues et al., 1991) was screened with a 4.6 kb cDNA probe (pOK1) containing the complete coding sequence of the MET gene (7195 to +4356) (Rodrigues et al., 1991) . Positive clones were selected, puri®ed and ampli®ed in LE392 bacteria as described previously (Cooper et al., 1984) . The Lawrence Livermore National Laboratory chromosome 7-speci®c cosmid library was screened with a MET cDNA probe corresponding to MET +3081 to +4406 to identify overlapping cosmid clones containing genomic DNA sequences not isolated from the phage library (obtained from Dr SW Scherer). DNA from each phage or cosmid clone was isolated as described in Maniatis et al. (1992) . and used in cycle sequencing reactions to determine intron ± exon boundaries of MET.
Cycle sequencing of phage and cosmid DNA
The appropriate puri®ed genomic DNA from phage or cosmid clones (500 ng) was used in cycle sequencing reactions with Met-speci®c primers to determine the intron ± exon junctions and¯anking intron sequences. These reactions were carried out using the GibcoBRL dsDNA Cycle Sequencing System (GibcoBRL, Burlington, Ontario) according to the instructions included in the kit. The sequences of the primers used for this purpose are available from the authors.
PCR to estimate intron sizes
To estimate the sizes of the introns of the MET gene, appropriate Met-speci®c oligonucleotide primers were generated and used in PCR reactions to amplify each individual intron. PCR for introns up to 4 kb in size was carried out in a ®nal volume of 50 mL, containing 100 ng genomic DNA prepared from one of two dierent cell lines (HeLa and Okajima), 1.5 mM MgCl 2 , 5 mL standard 106 PCR buer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 50 pmol of each primer, 1.25 mM dNTPs and 2.5 units of Taq polymerase (GibcoBRL, Burlington, Ontario). An initial step of 3 min at 858C was followed by 35 cycles of 40 s denaturation at 948C, 30 s of annealing at 558C, and 40 s of extension at 728C, followed by a ®nal extension step of 2 min at 728C. Introns between 2 kb and 6 kb were ampli®ed in conditions as described above, with the addition of 2.5 units of Taq extender PCR additive (Stratagene) and substituting the Taq extender buer for the regular PCR buer. Introns larger than 6 kb were ampli®ed using the Expand Long Template PCR System (Boehringer Mannheim) according to the instructions included in the kit. PCR products were analysed by electrophoresis of 1/10th of the reaction on a 1% agarose gel. The size of each intron was estimated by comparison of the PCR product with molecular size markers. Each intron was ampli®ed at least twice from two dierent cell lines. The sizes of all introns except 1 and 2 were estimated in this manner. The sizes of introns 1 and 2 were con®rmed from analysis of genomic DNA sequences of the appropriate portion of chromosome 7, available at the Washington University Human Genome Sequencing Project's World Wide Web site (http://genome.wustl.
-edu/gsc/gschmpg.html). The appropriate contig is H_RG253B13, which covers MET genomic DNA from exon 1 to exon 9. The estimated sizes of introns 3 to 8, obtained by PCR as described above, corresponded to the sizes as determined from analysis of this contig.
RNA analysis
Total RNA was isolated from various human cell lines by the method of Chomczynski and Sacchi (1987) . Poly(A) + RNA was twice selected on oligo(dT)-cellulose. For Northern blot analysis, poly(A) + RNA was denaturated with formamide and separated on a denaturing formamideformaldehyde agarose gel as described previously (Park et al., 1986) . Filters were hybridized for 48 h at 428C with 2610 6 c.p.m./ml of probe in hybridization buer (66SSC, 50% formamide, 56Denhardt, 1% SDS, 0.2 mg/ml salmon sperm DNA) and washed in 26SSC70.1% SDS at room temperature for 30 min, then three times in 0.26 SSC70.1% SDS at 658C (30 min each wash). Two MET derived probes were used. Probe A is derived from an EcoRV ± EcoRI fragment (position +641 to +2055). Probe B consists of an EcoRI ± EcoRV fragment located in position 7194 to +641 in the published sequence (Park et al., 1987) . Both probes were labeled with a-32 P-dCTP by random primer labeling (Feinberg and Vogelstein, 1983) .
Isolation of Met cDNA clones
A cDNA library was constructed from twice Poly(A) + selected RNA isolated from a gastric carcinoma cell line, Okajima (Rodrigues et al., 1991) . The cDNA was synthesized following the method of Gubler and Homan (1983) , semi-XhoI synthetic adaptors were added, and the cDNA was cloned into the XhoI site of the mammalian expression vector pXMT2. Approximately 10 6 colonies were screened using probes derived from Met cDNA (probe A, probe B as described above). Positive clones were puri®ed, and the longest clones were selected for sequencing using the dideoxynucleotide chain termination method with [a- 35 S]dATP (ICN Radiochemicals) and Sequenase (USB) as speci®ed by the manufacturers. Clones pOK14 and pOK8 were selected as putative representative cDNAs for the 7 kb Met mRNA, and were sequenced entirely by a combination of ExoIII-S1 nuclease deletion method and synthetic oligonucleotide-directed sequencing of subclones in pBluescript II KS + (pBS). PC/ Gene (IntelliGenetics Inc.) and MacVector (Oxford Molecular Group) software was used for data analysis.
S1 Nuclease protection analysis
A BamHI ± PvuII fragment isolated from the 5' end of pOK8 was end-labeled at the BamHI site (position +1964 in MET) with T4 DNA polymerase using standard protocols (Maniatis et al., 1992) . The labeled BamHI ± PvuII 2.0 kb fragment was puri®ed on a low melting agarose gel by extraction with phenol. The probe (25 000 c.p.m.) was hybridized to 50 mg total cellular RNA in 50 ml of 80% formamide, 400 mM NaCl, 40 mM PIPES (pH 6.7) and 1 mM EDTA. Samples were denatured at 858C for 10 min and incubated at 458C overnight. 450 ml of S1 digestion buer (30 mM NaOAc pH 4.6, 50 mM NaCl, 1 mM ZnSO 4 , 0.5% glycerol and 1000 U/ml of S1 nuclease) were added and the samples were incubated at 258C for 45 min, then transferred to 378C for 15 min. After addition of 20 mg yeast t-RNA, samples were ethanol precipitated, washed and resuspended in 80% formamide loading dye, heated for 10 min at 958C, chilled on ice, and loaded onto a 4% denaturing acrylamide:urea gel.
Reverse transcriptase-polymerase chain reaction (RT ± PCR) RT ± PCR was performed on single stranded cDNA. Brie¯y, total RNA was extracted from biopsies as described above. First-strand cDNA was synthesized from 4 mg total RNA using the Expand Reverse Transcriptase system (Boehringer Mannheim) with 50 pmol oligo (dT) 15 ± 18 primer (Pharmacia), according to the instructions provided. Three mL of the RT reaction was used for PCR in a ®nal volume of 50 mL, containing 1.5 mM MgCl 2 , 5 mL standard 106PCR buer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 50 pmol of each primer as indicated in Figure 5 , 1.25 mM dNTPs, and 2.5 units of Taq polymerase (GibcoBRL, Burlington, Ontario). An initial step of 3 min at 858C was followed by 35 cycles of 40 s of denaturation at 948C, 30 s of annealing at 558C, and 40 s of extension at 728C, followed by a ®nal extension step of 2 min at 728C. PCR products were analysed by electrophoresis in a 1% agarose gel. The primers used were: A=GACTT-CTCCACTGGTTCCTGG, which hybridizes to MET 744 to 724; B=ACAATGTGAGATGTCTCCAGC, which hybridizes to MET +1142 to +1162; and C=CCAAGATTAGCTATGGTGAGGTC, which hybridizes to MET +1367 to +1345.
Cell lines and transfections
The Okajima and MKN45 cell lines, derived from poorly dierentiated gastric carcinoma (Motoyama et al., 1979) , were obtained from Dr GF Vande Woude. The A549 cell line is derived from a lung carcinoma, SW620, Colo6 and Colo205 from colon carcinomas, HFS/15 from human foreskin ®broblasts, and KB from an epidermoid carcinoma. All lines were obtained from American Type Culture Collection. Cell lines were maintained in Dulbecco's modi®ed Eagle serum (DMEM) or RPMI medium, supplemented with 10% fetal bovine serum (Flow laboratories). Transient transfections into COS-1 cells were performed as described previously in (Rodrigues et al., 1991) .
Immunoprecipitation
Immunoprecipitations were carried out using a polyclonal anti-Met C-terminal peptide antibody (Ab144) (Rodrigues et al., 1991) . The immunoprecipitated proteins were collected on protein A-Sepharose (Pharmacia) and washed three times with RIPA buer. The proteins were separated on 8% SDS ± PAGE, transferred to nitrocellulose, and immunoblotted with Ab144. Immune complexes were identi®ed with horse radish peroxidase (HRP) conjugated Protein A and revealed by enhanced chemiluminescence (ECL) (Amersham).
